European Summit on Pharma and Biotech Patent Litigation 2022

Face-to-Face Event: Define, Shape and Create Patent Litigation Strategies and Mitigate Risks

Register Now
Hotel NH Collection Amsterdam Barbizon Palace
25-26 January, 2022

“After a year of remote working and networking, meet the Pharma and Biotech Patent Litigation community Face-to-Face to build stronger relationships.”

Alistair Ren-Healey, Portfolio Director

Join us in 2022

Register now to attend the European Summit on Pharma and Biotech Patent Litigation, taking place 25-26 January 2022.

This two-day industry led event will delve into current practical areas of legal IP uncertainties, with the leading minds of in-house representatives from both innovator and generic companies as well as prominent legal practitioners from Europe and Worldwide.

Join us as we bring together legal experts and academics to deliver:

① Crucial insights on risk-avert, cost-efficient patent litigation strategies 

② Tools to differentiate how your company maximises its ROI on patent rights and IP protection.

③ Methods to successfully defend post-filing patent litigation challenges

 A unique and targeted networking and relationship building platform

This event is set to be a significant opportunity for professionals working in Intellectual Property law, Patent Strategist, Senior Counsel, or IP.

Confirm your place to attend face-to-face, and ensure that your patents are protected in an increasingly competitive market. 

Life Sciences Patent Advisory Board

Author:

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Author:

Fredrick Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Author:

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Author:

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Author:

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Author:

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Download Agenda

Download the official event agenda to get a preview of our key sessions, thought-leading speakers, industry leading partners and all the compelling facets of the 2022 programme.

 

Download our Agenda

ATTEND WORKSHOPS

   

Workshop A

101 Refresher Masterclass: – Time to Refresh Your Technical Skills to Get Ready for The Unitary Patent Court

After countless delays, the long-awaited EU Unitary Patent and Unified Patent Court (UPC) look likely to be launched in 2022. While the UPC promises greater IP protection, it also means that if a company lost a case in a unified court, it would lose Europe-wide. Therefore, it is imperative to start preparation now and enhance your patent strategies for your portfolio. This interactive pre-conference workshop is specifically designed to provide a comprehensive and practical guide for in-house lawyers on how to make the most of the UPC system and avoid any potential pitfalls.

Secure your place at Pharma And Biotech Patent Litigation Europe Workshop A for €400!


Workshop B

Trade Secrets: Dissecting EU Trade Secret Directive: Directive (EU) 2016/943 and Successfully Implement the Legislation Into Practice

Protecting trade secret information is a critical competency for today’s life sciences industry. Companies need to establish sound practices, procedures, and policies to maintain confidentiality and reduce the prospect of misappropriation. In this dedicated workshop, you will learn how to build and enhance a trade secret protection framework to offer safeguards and protections against being compromised.

Secure your place at Pharma And Biotech Patent Litigation Europe Workshop B for €400!

WHO WILL BE THERE

2022 Speakers

 

Dominic Adair

Partner
Bristows

Dominic Adair

Partner
Bristows

Dominic Adair

Partner
Bristows
 

Rainer Becker

Head of Unit in Antitrust for Pharma and Health Services, DG Competition
European Commission

Rainer Becker

Head of Unit in Antitrust for Pharma and Health Services, DG Competition
European Commission

Rainer Becker

Head of Unit in Antitrust for Pharma and Health Services, DG Competition
European Commission
 

Koen Bijvank

Partner
Brinkhof

Koen Bijvank

Partner
Brinkhof

Koen Bijvank

Partner
Brinkhof
 

Sven Bostyn

Associate Professor of Biomedical Innovation Law
University of Copenhagen

Sven Bostyn

Associate Professor of Biomedical Innovation Law
University of Copenhagen

Sven Bostyn

Associate Professor of Biomedical Innovation Law
University of Copenhagen
 

Sara Burghart

Lead IP Litigation Counsel - Global Litigation & Launch
Sandoz

Sara Burghart

Lead IP Litigation Counsel - Global Litigation & Launch
Sandoz

Sara Burghart

Lead IP Litigation Counsel - Global Litigation & Launch
Sandoz
 

Robert Cerwinski

Managing Partner
Gemini Law

Robert Cerwinski

Managing Partner
Gemini Law

Robert Cerwinski

Managing Partner
Gemini Law
 

Brian Coggio

Attorney
Fish & Richardson

Brian Coggio

Attorney
Fish & Richardson

Brian Coggio

Attorney
Fish & Richardson
 

Liz Cohen

Partner
Bristows

Liz Cohen

Partner
Bristows

Liz Cohen

Partner
Bristows
 

Katie Coltart

Partner
Kirkland & Ellis

Katie Coltart

Partner
Kirkland & Ellis

Katie Coltart

Partner
Kirkland & Ellis
 

Kristin Cooklin

Head of Intellectual Property
Zentiva

Kristin Cooklin

Head of Intellectual Property
Zentiva

Kristin Cooklin

Head of Intellectual Property
Zentiva
 

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech
 

Jenny Davies

Partner
Gowling

Jenny Davies

Partner
Gowling

Jenny Davies

Partner
Gowling
 

Ricardo Dijkstra

Partner
Vondst

Ricardo Dijkstra

Partner
Vondst

Ricardo Dijkstra

Partner
Vondst
 

Robin Ellis

Partner
Reddie&Grose

Robin Ellis

Partner
Reddie&Grose

Robin Ellis

Partner
Reddie&Grose
 

Jules Fabre

Legal Director, Intellectual Property
Pinsent Masons

Jules Fabre

Legal Director, Intellectual Property
Pinsent Masons

Jules Fabre

Legal Director, Intellectual Property
Pinsent Masons
 

Fredrick Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrick Fredh

European Patent Attorney
Chr. Hansen

Fredrick Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

 

Katherine A. Helm

Partner
Dechert (USA)

Katherine A. Helm

Partner
Dechert (USA)

Katherine A. Helm

Partner
Dechert (USA)
 

Matt Hervy

Head of Artificial Intelligence Law
Gowling WLG

Matt Hervy

Head of Artificial Intelligence Law
Gowling WLG

Matt Hervy

Head of Artificial Intelligence Law
Gowling WLG
 

Sir Robin Jacob

Former Lord
Justice of Appeal

Sir Robin Jacob

Former Lord
Justice of Appeal

Sir Robin Jacob

Former Lord
Justice of Appeal
 

Rieke Kaup

DG Competition
European Commission

Rieke Kaup

DG Competition
European Commission

Rieke Kaup

DG Competition
European Commission
 

Lindsey Kent

Assistant General Patent Counsel
Eli Lilly

Lindsey Kent

Assistant General Patent Counsel
Eli Lilly

Lindsey Kent

Assistant General Patent Counsel
Eli Lilly
 

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma
 

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

 

Daan De Lange

Partner
Brinkhof

Daan De Lange

Partner
Brinkhof

Daan De Lange

Partner
Brinkhof
 

Alexander de Leeuw

Advocat
Brinkhof (NED)

Alexander de Leeuw is an experienced lawyer specialising in national and international patent litigation. 

He frequently litigates before the Dutch courts as well as the European Patent Office. Some examples of cases that Alexander worked on concern CRISPR-Cas9 (Broad/MIT/Harvard), pemetrexed (Sandoz), lithography machines (Carl Zeiss), and surgical laser systems (Alcon). 

He also regularly deals with and teaches about the protection of trade secrets, and has been involved in high-profile international trade secret litigation.

Alexander de Leeuw

Advocat
Brinkhof (NED)

Alexander de Leeuw

Advocat
Brinkhof (NED)

Alexander de Leeuw is an experienced lawyer specialising in national and international patent litigation. 

He frequently litigates before the Dutch courts as well as the European Patent Office. Some examples of cases that Alexander worked on concern CRISPR-Cas9 (Broad/MIT/Harvard), pemetrexed (Sandoz), lithography machines (Carl Zeiss), and surgical laser systems (Alcon). 

He also regularly deals with and teaches about the protection of trade secrets, and has been involved in high-profile international trade secret litigation.

 

Tessa M. Malmund-Cohen

Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals

Tessa M. Malmund-Cohen

Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals

Tessa M. Malmund-Cohen

Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
 

Patrick Mccutcheon

Senior Expert IP and Competition Law
European Commission

Patrick Mccutcheon

Senior Expert IP and Competition Law
European Commission

Patrick Mccutcheon

Senior Expert IP and Competition Law
European Commission
 

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
 

Arvid van Oorschot

Partner
Vondst

Arvid van Oorschot

Partner
Vondst

Arvid van Oorschot

Partner
Vondst
 

Jason Rice

Patent Attorey
GSK

Jason Rice

Patent Attorey
GSK

Jason Rice

Patent Attorey
GSK
 

Roberto Romandini

Legal Member of the Board of Appeal
EPO

Roberto Romandini

Legal Member of the Board of Appeal
EPO

Roberto Romandini

Legal Member of the Board of Appeal
EPO
 

Jon Singer

Principal
Fish & Richardson

Jon Singer

Principal
Fish & Richardson

Jon Singer

Principal
Fish & Richardson
 

Adrian Spillman

Director of Intellectual Property
Valneva

Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.

Adrian Spillman

Director of Intellectual Property
Valneva

Adrian Spillman

Director of Intellectual Property
Valneva

Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.

His areas of expertise include protection of prophylactics, therapeutics, and diagnostics for infectious diseases, immunological disorders, cancerous diseases, neurodegenerative disorders and metabolic disorders, vaccine technologies, antibody technologies, production of biological and chemical compounds, new medical uses, and formulations of known compounds.

After earning his Ph.D. at the University of Zurich, Switzerland, Adrian was a Consultant at Deloitte, followed by a 7-year stay in various positions in the patent department at Novartis. Furthermore, Adrian was Senior Patent Attorney at Ablynx, an antibody company in Belgium, for three years.

Adrian is a European and Swiss-registered patent attorney and received his LLM from the University of Law in London.

 

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH
 

Craig Svoboda

Global Head of IP
Albotech

Craig Svoboda

Global Head of IP
Albotech

Craig Svoboda

Global Head of IP
Albotech
 

Otto Swens

Partner
Vondst

Otto Swens

Partner
Vondst

Otto Swens

Partner
Vondst
 

Cecil Teles

Head Patent Attorney
Zentiva

Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.

Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.

Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.

Cecil Teles

Head Patent Attorney
Zentiva

Cecil Teles

Head Patent Attorney
Zentiva

Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.

Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.

Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.

Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.

 

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

Dean Thomas

Global Head of IP and Associate General Cousel
Ichnos Sciences

Our Partners

Become a Partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Saturday, November 20, 2021 to Friday, December 17, 2021
Tier 1
€1999
Early Bird rate until December 17 (Standard €2199)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
Saturday, November 20, 2021 to Friday, December 17, 2021
Tier 2
€1499
Early Bird rate until December 17 (Standard €1699)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us